LD-2 disclosure · 3rd Quarter - Report (No Activity)
EDISON PHARMACEUTICALS
Coverage · No income or expenses were reported on this filing.
Client
- Description
- Drug development for treatment of rare mitochondrial disease, TBI, and TON
- Location
- California · United States of America
Registrant
- Description
- Global trade
- Location
- Washington, District of Columbia, United States of America